# US 2017/0290896 A1 · Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0290896 A1
- Document ID: US20170290896A1
- Status: Published application
- Kind: A1
- Application number: 15/492,365
- Filed: 2017-04-20
- Published: 2017-10-12
- Earliest claimed: 2007-10-31
- Inventors: Carlos de Baeremaecker Barros
- Web page: https://patentgrep.com/patent/US20170290896A1

## CPC

- A61K 39/005: Trypanosoma antigens
- A61K 39/002: Protozoa antigens
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55527: {Interleukins}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of Trypanosoma cruzi fused to the C-terminal region. The vaccine further comprises an aluminum oxide adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion.

## Claims

### Claim 1

A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, said vaccine comprising, as active ingredient, an immunogenic component comprising a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, wherein each repetitive unit shows the following amino acid sequence:
AHSTPSTPVDSS
and wherein a polypeptide with trans-sialidase activity of Trypanosoma cruzi is fused to the C-terminal region, and
wherein the vaccine further comprises an adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion, wherein the adjuvant is aluminum oxide.

### Claim 2 (depends on 1)

The monocomponent vaccine of claim 1, wherein the C-terminal region of the immunogenic component is encoded by a polynucleotide having the nucleotide sequence of SEQ ID NO. 3.

### Claim 3 (depends on 1)

The monocomponent vaccine of claim 1, wherein the polypeptide with trans-sialidase activity of Trypanosoma cruzi has the amino acid sequence of SEQ ID NO. 2 and is encoded by the nucleotide sequence of SEQ ID NO. 1.

### Claim 4 (depends on 1)

The monocomponent vaccine of claim 1, further comprising one or more polynucleotides that comprise the regions which encode cytokines.

### Claim 5 (depends on 4)

The monocomponent vaccine of claim 4, wherein the cytokine is selected from interleukin 12 (IL-12), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 6 (IL-6), interleukin 18 (IL-18), γ-interferon, α,β-interferons and chemokines.

### Claim 6 (depends on 5)

The monocomponent vaccine of claim 5, where the cytokine is selected from the IL-12 and GM-CSF cytokines.

### Claim 7 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein the immunogenic component is selected from between 10 and 16 repetitive units in the C-terminal region.

### Claim 8 (depends on 1)

The monocomponent vaccine defined in claim 1, comprising a recombinant biomolecule formed by the fusion of that region which comprises repetitive units of amino acids and at least one of (i) the polypeptide with trans-sialidase activity, (ii) the polypeptide with cysteine proteinase activity, and (iii) the paraflagellar rod protein (PFR).

### Claim 9 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein the immunogen of the immunogenic component is obtained from Trypanosoma cruzi trypomastigotes.

### Claim 10 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein the immunogen of the immunogenic component is obtained from Trypanosoma cruzi amastigotes.

### Claim 11 (depends on 1)

The monocomponent vaccine defined in claim 1, which stimulates at least one immune response selected from an antibody response and an immune response by cell mediation.

### Claim 12 (depends on 11)

The monocomponent vaccine defined in claim 11, which stimulates at least one response of CD4+ Th1 biased T cells and CD8+ T cells.

### Claim 13 (depends on 12)

The monocomponent vaccine defined in claim 12, which stimulates at least one response CD8+ T cells.

### Claim 14 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein the polypeptide is selected from the TSA-1, ASP-1, ASP-2, hemolysin and Lyt1 proteins.

### Claim 15 (depends on 1)

The monocomponent vaccine of claim 1, wherein said vaccine is a therapeutic vaccine.

### Claim 16 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein said vaccine is a prophylactic vaccine.

### Claim 17 (depends on 1)

The monocomponent vaccine defined in claim 1, wherein the C-terminal region of the immunogenic component is a polypeptide having the amino acid sequence of SEQ ID NO. 4.

### Claim 18

A monocomponent vaccine comprising, as active ingredient, an effective amount of a polynucleotide codifying one or more immunogenic polypeptides derived from a Trypanosoma cruzi.

### Claim 19 (depends on 18)

The monocomponent vaccine defined in claim 18, comprising a recombinant biomolecule formed by the fusion of that region which comprises repetitive units of amino acids and at least one of (i) the polypeptide with trans-sialidase activity, (ii) the polypeptide with cysteine proteinase activity, and (iii) the paraflagellar rod protein (PFR).
